





Rolandic Arteriovenous Malformation (AVM)



4



- **Demographics:** Male; 37 years
- **Initial Presentation:** Chronic headache
- **Diagnosis:** Rolandic AVM
- **Pre-radiosurgery Treatment:** None
- **Pre-radiosurgery Presentation:** Chronic headache
- **Radiosurgery Treatment:**
Upfront (primary); Linac-based SRS for right, rolandic (motor cortex) AVM
- **Radiosurgery Dosimetry:**
 - Target volume: 6.3 cc
 - Marginal dose: 15.0 Gy
 - Marginal isodose: 75%
 - Maximum dose: 20.6 Gy
 - Minimum dose: 13.5 Gy
 - Average dose: 18.9 Gy
 - Number of isocenters: 1
- **Follow-Up Period:** 62 months post-SRS
- **Clinical Outcome:**
 - 6 months post-SRS: Persistence of annoying attacks of headache
 - 24 months post-SRS: Slightly improving headaches with medications
 - 60 months post-SRS: Persistence of mild attacks of headache
- **Complications:** None
- **Radiological Outcome:**
 - 6 months post-SRS (MRI): Stationary size of AVM nidus
 - 12 months post-SRS (MRI): Stationary size of AVM nidus
- 24 months post-SRS (MRI):
Stationary size of AVM nidus
Appearance of perinidal high signal in T2 and FLAIR studies, denoting vasogenic edema
- 36 months post-SRS (MRI):
Stationary size of AVM nidus
Increased perinidal high signal in T2 and FLAIR studies
Appearance of perinidal focal encephalomalacia showing heterogeneous enhancement in T1 Gadolinium-enhanced study
- 60 months post-SRS (MRI):
Slight decrease in size of AVM nidus
Persistent increased perinidal high signal in T2 and FLAIR studies
Persistence of perinidal heterogeneously enhancing focal encephalomalacia in T1 Gadolinium-enhanced study
- 61 months post-SRS (CT):
Persistence of perinidal heterogeneously enhancing focal encephalomalacia in contrast-enhanced study
- 62 months post-SRS (CTA): Residual smaller AVM nidus
- **Post-radiosurgery Treatment:** Watchful waiting for delayed complete obliteration of the residual AVM nidus during an extended follow-up period before deciding repeat radiosurgery treatment


















62 months F/U





Further Reading

- Cohen-Inbar O, Starke RM, Paisan G, et al. Early versus late arteriovenous malformation responders after stereotactic radiosurgery: an international multicenter study. *J Neurosurg.* 2017;127(3):503–11.
- Ellis TL, Friedman WA, Bova FJ, et al. Analysis of treatment failure after radiosurgery for arteriovenous malformations. *J Neurosurg.* 1998;89(1):104–11.
- Gallina P, Merienne L, Meder JF, et al. Failure in radiosurgery treatment of cerebral arteriovenous malformations. *Neurosurgery.* 1998;42(5):996–1002.

Hadjipanayis CG, Levy EI, Nirajna A, et al. Stereotactic radiosurgery for motor cortex region arteriovenous malformations. *Neurosurgery.* 2001;48(1):70–7.

Levegrün S, Hof H, Essig M, et al. Radiation-induced changes of brain tissue after radiosurgery in patients with arteriovenous malformations: dose/volume-response relations. *Strahlenther Onkol.* 2004;180(12):758–67.

Zabel-du Bois A, Milker-Zabel S, Huber P, et al. Stereotactic linac-based radiosurgery in the treatment of cerebral arteriovenous malformations located deep, involving corpus callosum, motor cortex, or brainstem. *Int J Radiat Oncol Biol Phys.* 2006;64(4):1044–8.